Cellectar Biosciences (NASDAQ:CLRB) initiated with Buy rating and $6 (180% upside) price target at Brookline Capital. Shares up 8% premarket.
Heat Biologics (NASDAQ:HTBX) initiated with Buy rating and $8 (999% upside) price target at Brookline Capital.
Progenics Pharmaceuticals (NASDAQ:PGNX) initiated with Buy rating and $10 (90% upside) price target at Brookline Capital.
Genomic Health (NASDAQ:GHDX) upgraded to Equal Weight with a $72 (1% downside risk) price target at Barclays. Downgraded to Hold with a $72 price target at Canaccord Genuity.
Zimmer Biomet Holdings (NYSE:ZBH) upgraded to Equal Weight with a $140 (4% upside) price target at Barclays.
Illumina (NASDAQ:ILMN) downgraded to Hold with a $300 (1% downside risk) price target at Canaccord. Shares down 1% premarket.
Pfizer (NYSE:PFE) downgraded to Neutral with a $41 (1% downside risk) price target at BofA Merrill Lynch. Downgraded to Equal Weight at Morgan Stanley.
Pieris Pharmaceuticals (NASDAQ:PIRS) downgraded to Neutral with a $5 (6% downside risk) price target at Baird. Shares down 4% premarket.
UniQure (NASDAQ:QURE) downgraded to Neutral at Guggenheim.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.